Spotlight Therapeutics

Hayward, United States Founded: 2017 • Age: 9 yrs
Cancer therapeutics are developed using targeted gene editing platforms.
Annual revenue - Latest available
Total funding $80.7M 5 rounds
Employees 32 Tracked headcount
Investors 6 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Spotlight Therapeutics

Spotlight Therapeutics is a company based in Hayward (United States) founded in 2017. Spotlight Therapeutics has raised $80.67 million across 5 funding rounds from investors including HHS, EPIQ and GordonMD Global Investments. The company has 32 employees as of December 31, 2022. Spotlight Therapeutics operates in a competitive market with competitors including Senti Biosciences, Beam Therapeutics, eGenesis, Annexon and TScan Therapeutics, among others.

  • Headquarter Hayward, United States
  • Employees 32 as on 31 Dec, 2022
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Spotlight Therapeutics Inc
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $80.67 M (USD)

    in 5 rounds

  • Latest Funding Round
    $533.94 K (USD), Grant

    Sep 21, 2023

  • Investors
    HHS

    & 5 more

  • Employee Count
    32

    as on Dec 31, 2022

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of Spotlight Therapeutics

Headcount 10-50
Employee Profiles 15
Board Members and Advisors 9
Employee Profiles
People
Mary Haak-Frendscho
President & CEO
People
Adam Silverman
VP, Protein Sciences
People
Cheng Li
VP, Business & Corporate Development
People
Peter Otoupal
Scientist II

Unlock access to complete

Board Members and Advisors
people
Patrick Hsu
Founder & Scientific Advisor
people
Krishna Yeshwant
Board Member
people
Craig Gordon
Board Member
people
Ron Levy
Scientific Advisor

Unlock access to complete

Funding Insights of Spotlight Therapeutics

Spotlight Therapeutics has successfully raised a total of $80.67M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $533.94 thousand completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Spotlight Therapeutics

Spotlight Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, EPIQ and GordonMD Global Investments.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investment management services are provided in the biopharmaceutical sector.
Locked Locked Locked
Diversified asset management services are offered by EPIQ.
Locked Locked Locked
Magnetic Ventures is focused on transforming healthcare through AI and biotech investments.
Locked Locked Locked
Premium access

Investor details for Spotlight Therapeutics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Spotlight Therapeutics

Investments
Premium access

Investment portfolio details for Spotlight Therapeutics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Spotlight Therapeutics

Premium access

Detailed financials for Spotlight Therapeutics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Spotlight Therapeutics Comparisons

Spotlight Therapeutics Primary company
Description
Cancer therapeutics are developed using targeted gene editin...
Location
Hayward, United States
Founded Year
2017
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
32
As of 2022
Premium access

Peer comparison for Spotlight Therapeutics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Spotlight Therapeutics

Spotlight Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Beam Therapeutics, eGenesis, Annexon and TScan Therapeutics, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Cell-based therapies for cancer treatment are developed.
Locked Locked Locked
Developer of gene therapy using CRISPR base editing to treat diseases
Locked Locked Locked
Gene transplantation platform for humanizing pig cells is developed.
Locked Locked Locked
Developer of antibodies to treat complement-mediated neurodegenerative diseases
Locked Locked Locked
T cell-based treatments for immunological and oncological disorders are developed.
Locked Locked Locked
CAR-T and TIL immunotherapies for solid tumors are developed.
Premium access

Detailed competitors of Spotlight Therapeutics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Spotlight Therapeutics

Premium access

Complete news archive for Spotlight Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Spotlight Therapeutics

Spotlight Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Spotlight Therapeutics is headquartered in Hayward, United States. It is registered at Hayward, California, United States.

Spotlight Therapeutics is a funded company, having raised a total of $80.67M across 5 funding rounds to date.

As of Dec 31, 2022, the latest employee count at Spotlight Therapeutics is 32.

Founded in 2017 and based in Hayward, United States, the company focuses on biotechnology in the oncology sector. Cancer therapeutics are developed through a proprietary platform called TAGE, by which CRISPR nuclease effectors are delivered to selected cells in vivo. A pipeline is maintained for applications in immuno-oncology, hematology, and ophthalmology, with operations centered on advancing gene editing technologies for therapeutic use.

Spotlight Therapeutics's top competitors include Hummingbird Bioscience, Lyell Immunopharma and eGenesis.

Spotlight Therapeutics has 6 investors. Key investors include HHS, EPIQ, GordonMD Global Investments, Magnetic Ventures, and Google Ventures.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available